中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

41 records (took 0.022 seconds)

    HUMAN FGF RECEPTOR AND ß-KLOTHO BINDING PROTEINS
    1.
    发明申请
    HUMAN FGF RECEPTOR AND ß-KLOTHO BINDING PROTEINS 审中-公开
    人FGF受体和ß-KLOTHO结合蛋白

    公开(公告)号：WO2011130417A3

    公开(公告)日：2012-03-08

    申请号：PCT/US2011032333

    申请日：2011-04-13

    Applicant: AMGEN INC ,  FACHINI ROGER ,  FOLTZ IAN ,  HAN SEOG JOON ,  HARRIS SUSIE MIKI ,  HU SHAW-FEN SYLVIA ,  KING CHADWICK TERENCE ,  LI YANG ,  LU JI ,  MICHAELS MARK LEO ,  SUN JEONGHOON

    Inventor： FACHINI ROGER ,  FOLTZ IAN ,  HAN SEOG JOON ,  HARRIS SUSIE MIKI ,  HU SHAW-FEN SYLVIA ,  KING CHADWICK TERENCE ,  LI YANG ,  LU JI ,  MICHAELS MARK LEO ,  SUN JEONGHOON

    IPC: C07K16/28 ,  A61K39/395 ,  A61P3/10

    CPC classification number: A61K39/3955 ,  C07K16/2863 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/32 ,  C07K2317/75 ,  C07K2317/92 ,  C07K2319/75

    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins and antigen binding protein-FGF21 fusions that specifically bind to ß-Klotho, or ß-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins and antigen binding protein-FGF21 fusions induce FGF21-like signaling. In some embodiments, an antigen binding protein or antigen binding protein-FGF21 fusion antigen binding component is a fully human, humanized, or chimeric antibody, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to ß-Klotho, or ß-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins and antigen binding protein-FGF21 fusions, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.

    Abstract translation: 本发明提供与抗原结合蛋白和特异性结合ß-Klotho或ß-Klotho以及FGFR1c，FGFR2c，FGFR3c和FGFR4中的一种或多种的抗原结合蛋白和抗原结合蛋白-FGF21融合物相关或衍生的组合物和方法。 在一些实施方案中，抗原结合蛋白和抗原结合蛋白FGF21融合物诱导FGF21样信号传导。 在一些实施方案中，抗原结合蛋白或抗原结合蛋白-FGF21融合抗原结合组分是完全人，人源化或嵌合抗体，这种抗体的结合片段和衍生物，以及特异性结合ß-Klotho或ß- Klotho和FGFR1c，FGFR2c，FGFR3c和FGFR4中的一种或多种。 其他实施方案提供编码这种抗原结合蛋白和抗原结合蛋白-FGF21融合体的核酸，及其片段和衍生物，以及多肽，包含这种多核苷酸的细胞，制备这种抗原结合蛋白的方法和抗原结合蛋白-FGF21融合物， 其衍生物和多肽，以及使用这种抗原结合蛋白和抗原结合蛋白-FGF21融合体，其片段和衍生物和多肽的方法，包括治疗或诊断患有2型糖尿病，肥胖症，NASH，代谢综合征和 相关疾病或病症。

    HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
    2.
    发明申请
    HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS 审中-公开
    人FGF受体和ß-KLOTHO结合蛋白

    公开(公告)号：WO2011130417A2

    公开(公告)日：2011-10-20

    申请号：PCT/US2011/032333

    申请日：2011-04-13

    Applicant: AMGEN INC. ,  FACHINI, Roger ,  FOLTZ, Ian ,  HAN, Seog Joon ,  HARRIS, Susie Miki ,  HU, Shaw-Fen Sylvia ,  KING, Chadwick Terence ,  LI, Yang ,  LU, Ji ,  MICHAELS, Mark Leo ,  SUN, Jeonghoon

    Inventor： FACHINI, Roger ,  FOLTZ, Ian ,  HAN, Seog Joon ,  HARRIS, Susie Miki ,  HU, Shaw-Fen Sylvia ,  KING, Chadwick Terence ,  LI, Yang ,  LU, Ji ,  MICHAELS, Mark Leo ,  SUN, Jeonghoon

    IPC: C07K16/28

    CPC classification number: A61K39/3955 ,  C07K16/2863 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/32 ,  C07K2317/75 ,  C07K2317/92 ,  C07K2319/75

    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins and antigen binding protein-FGF21 fusions that specifically bind to β-Klotho, or β-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins and antigen binding protein-FGF21 fusions induce FGF21-like signaling. In some embodiments, an antigen binding protein or antigen binding protein-FGF21 fusion antigen binding component is a fully human, humanized, or chimeric antibody, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to β-Klotho, or β-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins and antigen binding protein-FGF21 fusions, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.

    Abstract translation: 本发明提供与抗原结合蛋白和特异性结合ß-Klotho或ß-Klotho以及FGFR1c，FGFR2c，FGFR3c和FGFR4中的一种或多种的抗原结合蛋白和抗原结合蛋白-FGF21融合物相关或衍生的组合物和方法。 在一些实施方案中，抗原结合蛋白和抗原结合蛋白FGF21融合物诱导FGF21样信号传导。 在一些实施方案中，抗原结合蛋白或抗原结合蛋白-FGF21融合抗原结合组分是完全人，人源化或嵌合抗体，这种抗体的结合片段和衍生物，以及特异性结合ß-Klotho或ß- Klotho和FGFR1c，FGFR2c，FGFR3c和FGFR4中的一种或多种。 其他实施方案提供编码这种抗原结合蛋白和抗原结合蛋白-FGF21融合体的核酸，及其片段和衍生物，以及多肽，包含这种多核苷酸的细胞，制备这种抗原结合蛋白的方法和抗原结合蛋白-FGF21融合物， 其衍生物和多肽，以及使用这种抗原结合蛋白和抗原结合蛋白-FGF21融合体，其片段和衍生物和多肽的方法，包括治疗或诊断患有2型糖尿病，肥胖症，NASH，代谢综合征和 相关疾病或病症。

    ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
    10.
    发明申请
    ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF 审中-公开
    抗体依赖于A6和其使用

    公开(公告)号：WO2008112004A2

    公开(公告)日：2008-09-18

    申请号：PCT/US2007/075120

    申请日：2007-08-02

    Applicant: ASTRAZENECA AB ,  FOLTZ, Ian ,  RINKENBERGER, Julie ,  ALFRED, Avril ,  BARRY, Simon Thomas ,  BEDIAN, Vahe

    Inventor： FOLTZ, Ian ,  RINKENBERGER, Julie ,  ALFRED, Avril ,  BARRY, Simon Thomas ,  BEDIAN, Vahe

    IPC: C07K16/00

    CPC classification number: C07K16/2839 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  C12N5/0686 ,  C12N2501/998

    Abstract: Targeted binding agents, such antibodies directed to the antigen αVβ6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen αVβ6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed.

    Abstract translation: 描述了靶向结合剂，针对抗原aVβ6的这种抗体以及这些药剂的用途。 特别地，公开了针对抗原aVβ6的完全人单克隆抗体。 编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是从FR1至FR4或CDR1至CDR3 被披露。 还公开了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。

Patent Agency Ranking